Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Discovery Grants Program - Individual

University of Manitoba

$43,000.00

Control strategies for mammalian cell bioprocesses in the production of glycosylated biopharmaceuticals

FY 2019-20

Summary
Mammalian cell technology is the basis for the production of an increasing number of biopharmaceuticals used as therapeutics for unmet medical needs. This proposal aims to control the production bioprocesses to enable high yield of these glycoproteins with the critical quality attributes that ensure high bioactivity. The research will be conducted in a laboratory which has facilities for mammalian cell culture as well as bioanalytical tools for the analysis of recombinant products and their glycosylation profiles.***The proposal will be conducted through a series of projects, each of which will be related to the training of up to 6 graduate students over the course of the program. (a) Chemostat cultures of antibody-secreting Chinese hamster ovary (CHO) cells will be established to assess the effect of culture parameters on the monoclonal antibody (Mab) yield and glycosylation profile. The parameters will include pH, dissolved oxygen and nutrient concentrations, particularly glucose, galactose and glutamine. Steady-state metabolism of the cells will be established following incremental step changes of these parameters. Nutrient uptake rates and steady state intracellular concentrations of critical precursors such as nucleotide sugars will be measured to obtain data that may be used to develop predictive models for product yields and glycosylation profiles. (b) Enzymic re-modelling will be implemented during the purification of Mabs produced in the bioreactor using a solid state technique that we have previously developed. It will be attempted to obtain high yields of single glycoform entities by studying the kinetics of enzymic conversions using selected enzymes that have just been made commercially available. (c) Culture conditions that result in potentially immunogenic glycan forms will be characterized. This will include the glycolyl neuraminic acid and gal1-3gal epitopes. As well as CHO cells, this project will use mouse cells (NS0) because of their propensity to form such epitopes. (d) Chemically-defined, animal-component-free and serum-free medium will be developed for the growth and productivity of difficult cell lines such as the anchorage-dependent cells used in viral vaccine production. ***These projects will be conducted with the use of industrially-relevant cell lines that are available and have been used in preliminary studies. These include CHO cell lines that secrete a number of recombinant products such as humanized Mabs, chimeric human-llama Mabs and tissue-specific plasminogen activator (t-PA). Each of these products has a distinctive structure that can affect glycosylation profiles that are critical for their function. Where possible the structural profiles obtained in the studies will be related to functional assays. These studies are important to strategic developments in the implementation of platform technologies to be used in industrial bioprocesses. **
Program
Discovery Grants Program - Individual
Location
Manitoba, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
RGPIN-2016-05922
Name nom
Butler, Michael
Department département
Microbiology
Organization id
19
Institution établissement
University of Manitoba
Province en
Manitoba
Province fr
Manitoba
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2019
Competition year année de concours
2016
Award amount
43000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1511
Committee name en
Materials and Chemical Engineering
Committee name fr
Génie chimique et des matériaux
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
1802
Research subject group en
Chemical engineering
Research subject group fr
Génie chimique
Research subject en
Biochemical engineering
Research subject fr
Génie biochimique
Installment
inst:4 - 5
Partie
4
Nb partie
5
Application title
Control strategies for mammalian cell bioprocesses in the production of glycosylated biopharmaceuticals
Keyword
NSERC
Application summary
Mammalian cell technology is the basis for the production of an increasing number of biopharmaceuticals used as therapeutics for unmet medical needs. This proposal aims to control the production bioprocesses to enable high yield of these glycoproteins with the critical quality attributes that ensure high bioactivity. The research will be conducted in a laboratory which has facilities for mammalian cell culture as well as bioanalytical tools for the analysis of recombinant products and their glycosylation profiles.***The proposal will be conducted through a series of projects, each of which will be related to the training of up to 6 graduate students over the course of the program. (a) Chemostat cultures of antibody-secreting Chinese hamster ovary (CHO) cells will be established to assess the effect of culture parameters on the monoclonal antibody (Mab) yield and glycosylation profile. The parameters will include pH, dissolved oxygen and nutrient concentrations, particularly glucose, galactose and glutamine. Steady-state metabolism of the cells will be established following incremental step changes of these parameters. Nutrient uptake rates and steady state intracellular concentrations of critical precursors such as nucleotide sugars will be measured to obtain data that may be used to develop predictive models for product yields and glycosylation profiles. (b) Enzymic re-modelling will be implemented during the purification of Mabs produced in the bioreactor using a solid state technique that we have previously developed. It will be attempted to obtain high yields of single glycoform entities by studying the kinetics of enzymic conversions using selected enzymes that have just been made commercially available. (c) Culture conditions that result in potentially immunogenic glycan forms will be characterized. This will include the glycolyl neuraminic acid and gal1-3gal epitopes. As well as CHO cells, this project will use mouse cells (NS0) because of their propensity to form such epitopes. (d) Chemically-defined, animal-component-free and serum-free medium will be developed for the growth and productivity of difficult cell lines such as the anchorage-dependent cells used in viral vaccine production. ***These projects will be conducted with the use of industrially-relevant cell lines that are available and have been used in preliminary studies. These include CHO cell lines that secrete a number of recombinant products such as humanized Mabs, chimeric human-llama Mabs and tissue-specific plasminogen activator (t-PA). Each of these products has a distinctive structure that can affect glycosylation profiles that are critical for their function. Where possible the structural profiles obtained in the studies will be related to functional assays. These studies are important to strategic developments in the implementation of platform technologies to be used in industrial bioprocesses. **
University of Manitoba - $43,000 Grant (2019-20) | Canada Spends